Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H15N5O2 |
| Molecular Weight | 213.237 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NNC1=NN=C(C=C1)N(CCO)CCO
InChI
InChIKey=POFDNYKJHWKGDU-UHFFFAOYSA-N
InChI=1S/C8H15N5O2/c9-10-7-1-2-8(12-11-7)13(3-5-14)4-6-15/h1-2,14-15H,3-6,9H2,(H,10,11)
Oxdralazine is a peripheral vasodilator that was studied for patients with severe essential hypertension. The clinical trial has shown that at the end of the third month 25 patients on the triple regimen (chlorthalidone plus oxdralazine plus propranolol) achieved a stable diastolic blood pressure of 90 mm Hg or less. However, information about the further development of this drug is not available.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Disposition and metabolism of 3-hydrazino-6-[N,N-bis(2-hydroxyethyl)amino] pyridazine dihydrochloride in man. | 1979 |
|
| Long-term study of oxdralazine in hypertensive patients. | 1979 |
|
| Metabolites of 3-hydrazino-6-[bis-(2-hydroxyethyl)amino]pyridazine dihydrochloride in rat urine. | 1979 |
|
| Synthesis of three metabolites of 3-hydrazino-6-[bis-(2-hydroxyethyl)amino]pyridazine. A new rearrangement of 3-[1-methylethyliden)hydrazino] derivative. | 1978-08 |
|
| Antihypertensive and antidiuretic effects of 3-hydrazino-6-[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) in rats. | 1978-06 |
|
| Clinical and haemodynamic study of a new vasodilator drug L6150 (3-[bis-(2-hydroxyethyl)amino]-6-hydrazinopyridazine) in man. | 1976-12 |
|
| A comparative study of the hemodynamic effects of single intravenous doses of 3-hydrazino-6-[N,N-bis-(2-hydroxyethyl)-amino]-pyridazine-dihydrochloride and hydralazine. | 1976 |
|
| Systemic and coronary haemodynamic effects of the new hypotensive drug L 6150. | 1976 |
|
| Onthe pharmacology of 3-hydrazino-6-(N,N-bis(2-hydroxyethyl)amino)-pyridazine-dihydrochloride (L 6150). | 1973-11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7379444
Oxdralazine was given orally in doses of 15 to 30 mg to 7 subjects with hypertension
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Wed Apr 02 09:57:15 GMT 2025 , Edited by admin on Wed Apr 02 09:57:15 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
28434
Created by
admin on Wed Apr 02 09:57:15 GMT 2025 , Edited by admin on Wed Apr 02 09:57:15 GMT 2025
|
PRIMARY | |||
|
SUB09511MIG
Created by
admin on Wed Apr 02 09:57:15 GMT 2025 , Edited by admin on Wed Apr 02 09:57:15 GMT 2025
|
PRIMARY | |||
|
C80882
Created by
admin on Wed Apr 02 09:57:15 GMT 2025 , Edited by admin on Wed Apr 02 09:57:15 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104718
Created by
admin on Wed Apr 02 09:57:15 GMT 2025 , Edited by admin on Wed Apr 02 09:57:15 GMT 2025
|
PRIMARY | |||
|
DTXSID30169351
Created by
admin on Wed Apr 02 09:57:15 GMT 2025 , Edited by admin on Wed Apr 02 09:57:15 GMT 2025
|
PRIMARY | |||
|
100000083055
Created by
admin on Wed Apr 02 09:57:15 GMT 2025 , Edited by admin on Wed Apr 02 09:57:15 GMT 2025
|
PRIMARY | |||
|
C006198
Created by
admin on Wed Apr 02 09:57:15 GMT 2025 , Edited by admin on Wed Apr 02 09:57:15 GMT 2025
|
PRIMARY | |||
|
K6SU81C9V1
Created by
admin on Wed Apr 02 09:57:15 GMT 2025 , Edited by admin on Wed Apr 02 09:57:15 GMT 2025
|
PRIMARY | |||
|
17259-75-5
Created by
admin on Wed Apr 02 09:57:15 GMT 2025 , Edited by admin on Wed Apr 02 09:57:15 GMT 2025
|
PRIMARY | |||
|
4322
Created by
admin on Wed Apr 02 09:57:15 GMT 2025 , Edited by admin on Wed Apr 02 09:57:15 GMT 2025
|
PRIMARY |
ACTIVE MOIETY